Zhengye Biotechnology Holding (ZYBT) Price to Book (2025)
Zhengye Biotechnology Holding's (ZYBT) quarterly Price to Book came in at 1.26 in Q4 2025, down 76.44% quarter-over-quarter from 5.35 in Q2 2025.
Powered by 
Analysis
Zhengye Biotechnology Holding (ZYBT) Price to Book (2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Price to Book for 1 consecutive years, with 1.26 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Price to Book changed N/A year-over-year to 1.26 in Q4 2025; TTM through Dec 2025 was 1.26, a N/A change from a year earlier, with the FY2025 full-year figure at 1.24, changed N/A from the prior year.
- Price to Book was 1.26 for Q4 2025 at Zhengye Biotechnology Holding, down from 5.35 in the prior quarter.
- Over five years, Price to Book peaked at 5.35 in Q2 2025 and troughed at 1.26 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - |